MarketResearch.biz delivers in-depth insights on the global glycated albumin market in its upcoming report titled, “Global Glycated Albumin Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The global drugs market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global glycated albumin market report has been segmented on the basis of product type, application, and region.
This report is based on synthesis, analysis, and interpretation of information gathered regarding the target market from various sources. Our analysts have analysed the information and data and gained insights using a mix of primary and secondary research efforts with the primary objective to provide a holistic view of the market. In addition, an in-house study has been made of the global economic conditions and other economic indicators and factors to assess their respective impact on the market historically, as well as the current impact in order to make informed forecasts about the scenarios in future.
Glycated albumin determines medication regimens and doses, assessing overall therapy efficacy when diabetes therapy is initiated. Glycated albumin provides rapid indication of treatment efficacy or disease state deterioration when compared to glycated hemoglobin.
Increasing prevalence of diabetes is a major factor expected to support the growth of the global glycated albumin market over the forecast period. According to World Health Organization, the number of people with diabetes had grown from 108 Mn in 1980 to 422 Mn in 2014 and the prevalence has been rising more rapidly in middle- and low-income countries. Companies focusing on development of innovative and novel glycated albumin products is expected to fuel growth of the global glycated albumin market over the forecast period. In addition, increasing number of product approvals and subsequent launch of the same, with a view to gain competitive edge is expected to support growth of the market.
Based on product type, the global glycated albumin market is segmented based on human glycated albumin and animal glycated albumin. The human glycated segment accounts for major revenue share and is expected to witness rapid growth rate over the forecast period.
North America market dominates the global glycated albumin market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to presence of significant market players and high adoption of advance technologies in the region. Europe accounts for second-largest revenue share contribution to the global glycated albumin market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively. The market in the Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years. Increasing prevalence of diabetes coupled with increasing number of product approvals are major factors expected to support growth of the market in the region over the forecast period.
Target audience for the global glycated albumin market includes industry associations, glycated albumin manufacturers, hospitals, diagnostic centers, research institutes, medical device suppliers, government and research organizations, industrial and association bodies, and others.
Global glycated albumin market segmentation, by product type:
- Human Glycated Albumin
- Animal Glycated Albumin
Global glycated albumin market segmentation, by application:
Global glycated albumin market segmentation, by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2017 Estimated Year 2018 Forecast Period 2018–2028 Revenue in US$
- Asahi Kasei Pharma Corporation
- Lifespan Biosciences, Inc.
- Biomatik Corporation
- Abbexa Ltd.
- DRG International, Inc.
- Amsbio LLC
- Signalway Antibody LLC
- United States Biological Corp.
- Diazyme Laboratories
- Abnova Corporation
- Maccura Biotechnology Co. Ltd.
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!